LUGPA 2025 Global Prostate Cancer Congress CME Program   

	Disclaimer: Participants who previously attended the live LUGPA 2025 GPCC Program and claimed CME are not eligible to claim CME credit for the corresponding enduring activity.

COMING SOON!

Access the course on January 10, 2026 by logging into LUGPALearn with your single sign on.   

Course Description:

Adapted from the LUGPA 2025 Global Prostate Cancer Congress (GPCC), this enduring educational activity provides practicing clinicians with comprehensive, up-to-date education on the biology, diagnosis, and management of prostate cancer across the disease continuum. The program reviews foundational mechanisms driving prostate cancer development and progression, including key genetic and molecular factors, and examines current and emerging approaches to screening, diagnosis, and risk stratification.

Through expert-led presentations and evidence-based discussions, learners will evaluate contemporary diagnostic tools such as advanced imaging modalities and biopsy techniques, and compare treatment strategies for localized, advanced, and metastatic disease. The activity also addresses practical considerations in patient care, including the management of treatment-related side effects and complications, with an emphasis on preserving quality of life.

Finally, the program explores emerging research and future directions in prostate cancer care, including advances in genetic testing, immunotherapy, radioligand therapy, and personalized medicine, as well as relevant legislative and policy considerations that may impact patient access and clinical practice. This activity is designed to support clinicians in delivering informed, patient-centered, and guideline-concordant prostate cancer care.

Learning Objectives:

After the LUGPA 2025 GPCC Enduring Program, learners will be able to: 

1. Describe the biological mechanisms and genetic factors involved in the development and progression of prostate cancer.
2. Evaluate the current screening methods for prostate cancer, such as PSA testing and digital rectal exams, and understand their benefits and limitations.
3. Describe the various diagnostic approaches, including imaging modalities (MRI, CT, PET scans) and biopsy techniques, as well as staging criteria for prostate cancer.
4. Compare and contrast the various treatment options for localized and advanced prostate cancer, including surgery, radiation therapy, hormone therapy, chemotherapy, and emerging treatments.
5. Develop strategies for managing the side effects and complications of prostate cancer treatments, including urinary incontinence, sexual dysfunction, and metabolic changes.
6. Explore the latest research findings and future directions in prostate cancer, including advancements in genetic testing, immunotherapy, and personalized medicine. Review and appraise resources about legislation related to prostate cancer.

Accreditation and Designation Statement  

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUPGA. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 9.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activities.

The Enduring approval period is: January 10, 2026 – January 10, 2029

GPCC 2025 Enduring Program Accreditation Statements.pdf

Overarching Sessions Include: 

Men’s Health Issues  
Risk Stratified Approach to diagnosing Prostate Cancer 
Role of Genomics and Genetics in Prostate Cancer  
Health Policy and Political Advocacy
Molecular Targeted Imaging  
Localized Prostate Cancer 
Advanced Prostate Cancer 
Advanced Prostate Cancer 
Preventing and treating side effects

View the full agenda for a complete list of subsessions.